Karin Schölin Bywall
Karin Schölin Bywall
Postdoc researcher
PhD
Karin Schölin Bywall is a postdoc researcher at CRB. She explores patients' preferences and perspectives on individualized treatment using prediction algorithms and digital health applications. The research is part of the NordForsk funded Personalized Medicine in RA by combining genomics, biomarkers, clinical and patient-derived data from the Nordic countries (NORA) project that will develop ways to tailor treatment for individual patients and to integrate patients' own benefit-risk tradeoffs in individualized treatment using digital tools. Karin Schölin Bywall is working with both qualitative exploration and quantitative preference elicitation methods, to explore how people balance their interests and values. She is also part of the IMI-funded PREFER project aiming to investigate methodologies to elicit informed patient preferences regarding the benefits and risks of drugs, from development through the entire cycle, to inform the decision-making process by regulators and HTA bodies.
Email: karin.bywall@crb.uu.se
Recently in the media
- ”Vägen till rätt medicin kan kortas om patienten får vara med i samtalet”
Elsa Science, 2021-06-22 - “A dialogue with the patient can shorten the path to the right medication”
Elsa Science, 2021-06-22 - Patienters syn på att inkluderas i forskning om läkemedel
Reumatikerförbundet, 2018-12-18 - Study explores patient preferences in second-line RA treatment
AJMC, 2021-01-23
Publications
-
How can patient preferences be used and communicated in the regulatory evaluation of medicinal products?: Findings and recommendations from IMI PREFER and call to action
Part of Frontiers in Pharmacology, 2023.
DOI for How can patient preferences be used and communicated in the regulatory evaluation of medicinal products?: Findings and recommendations from IMI PREFER and call to action Download full text (pdf) of How can patient preferences be used and communicated in the regulatory evaluation of medicinal products?: Findings and recommendations from IMI PREFER and call to action
-
Physical function and severe side effects matter most to patients with RA (< 5 years): a discrete choice experiment assessing preferences for personalized RA treatment
Part of BMC Rheumatology, 2023.
DOI for Physical function and severe side effects matter most to patients with RA (< 5 years): a discrete choice experiment assessing preferences for personalized RA treatment Download full text (pdf) of Physical function and severe side effects matter most to patients with RA (< 5 years): a discrete choice experiment assessing preferences for personalized RA treatment
-
Making space for patients’ preferences in precision medicine: a qualitative study exploring perspectives of patients with rheumatoid arthritis
Part of BMJ Open, p. e058303-e058303, 2022.
DOI for Making space for patients’ preferences in precision medicine: a qualitative study exploring perspectives of patients with rheumatoid arthritis Download full text (pdf) of Making space for patients’ preferences in precision medicine: a qualitative study exploring perspectives of patients with rheumatoid arthritis
-
Exploring preferences of at-risk individuals for preventive treatments for rheumatoid arthritis
Part of Scandinavian Journal of Rheumatology, p. 1-11, 2022.
-
Would you consider donating your left-over embryos to treat Parkinson’s disease? Interviews with individuals that underwent IVF in Sweden
Part of BMC Medical Ethics, 2022.
DOI for Would you consider donating your left-over embryos to treat Parkinson’s disease? Interviews with individuals that underwent IVF in Sweden Download full text (pdf) of Would you consider donating your left-over embryos to treat Parkinson’s disease? Interviews with individuals that underwent IVF in Sweden
-
Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania
Part of Rheumatology, 2022.
DOI for Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania Download full text (pdf) of Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania
-
Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis
Part of Clinical Rheumatology, p. 695-704, 2022.
DOI for Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis Download full text (pdf) of Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis
-
Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations
Part of Arthritis Research & Therapy, 2022.
DOI for Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations Download full text (pdf) of Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations
Risk information
We are investigating risk information from serval perspectives.
Patient preferences
Giving patients a voice in drug development
PREFER is a five year public-private research project where academic researchers and the pharmaceutical industry work together to find out when and where patients want, can and should be involved in drug development
Personalized medicine & preferences
Rheumatoid Arthritis
The NordForsk funded NORA project will develop new ways to tailor treatment for individual patients and to integrate patients' own tradeoffs in individualized treatment using digital tools.
Methodology, rheumatoid arthritis and patient involvement
Drugs should benefit patients. By extension, they should have a say in designing research meant to find out what they think about drugs. Here, Karin Schölin Bywall shares her thoughts about involving patients in research and working together with stakeholders.
